Treatment decisions are guided by oncogenic driver mutations, with the Epidermal Growth Factor Receptor (EGFR) mutation being the most common in non-smoking NSCLC patients—particularly among East Asian women where prevalence reaches up to 74 % [4], [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.